These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 23145120)
21. Discovery of 5-(3-Chlorophenylamino)benzo[ Wang Y; Lv Z; Chen F; Wang X; Gou S J Med Chem; 2021 Apr; 64(8):5082-5098. PubMed ID: 33834781 [TBL] [Abstract][Full Text] [Related]
22. Casein kinase 2 inhibitor CX-4945 elicits an anti-Warburg effects through the downregulation of TAp73 and inhibits gastric tumorigenesis. Tang S; Yuan Y; Liu Z; He Y; Pan D Biochem Biophys Res Commun; 2020 Oct; 530(4):686-691. PubMed ID: 32771361 [TBL] [Abstract][Full Text] [Related]
23. Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer. Jung M; Park KH; Kim HM; Kim TS; Zhang X; Park SM; Beom SH; Kim HS; Cheong JH; Chung HC; Soong J; Lin SC; Rha SY Gastric Cancer; 2019 Nov; 22(6):1153-1163. PubMed ID: 31098863 [TBL] [Abstract][Full Text] [Related]
24. Effect of Simultaneous Inhibition of Protein Kinase CK2 and Thymidylate Synthase in Leukemia and Breast Cancer Cells. Wińska P; Skierka K; Łukowska-Chojnacka E; Koronkiewicz M; Cieśla J; Bretner M Anticancer Res; 2018 Aug; 38(8):4617-4627. PubMed ID: 30061228 [TBL] [Abstract][Full Text] [Related]
26. CK2 blockade causes MPNST cell apoptosis and promotes degradation of β-catenin. Kendall JJ; Chaney KE; Patel AV; Rizvi TA; Largaespada DA; Ratner N Oncotarget; 2016 Aug; 7(33):53191-53203. PubMed ID: 27448963 [TBL] [Abstract][Full Text] [Related]
27. Therapeutic CK2 inhibition attenuates diverse prosurvival signaling cascades and decreases cell viability in human breast cancer cells. Gray GK; McFarland BC; Rowse AL; Gibson SA; Benveniste EN Oncotarget; 2014 Aug; 5(15):6484-96. PubMed ID: 25153725 [TBL] [Abstract][Full Text] [Related]
28. CX-4945: the protein kinase CK2 inhibitor and anti-cancer drug shows anti-fungal activity. Masłyk M; Janeczko M; Martyna A; Kubiński K Mol Cell Biochem; 2017 Nov; 435(1-2):193-196. PubMed ID: 28501934 [TBL] [Abstract][Full Text] [Related]
29. Discovery and design of tricyclic scaffolds as protein kinase CK2 (CK2) inhibitors through a combination of shape-based virtual screening and structure-based molecular modification. Sun H; Xu X; Wu X; Zhang X; Liu F; Jia J; Guo X; Huang J; Jiang Z; Feng T; Chu H; Zhou Y; Zhang S; Liu Z; You Q J Chem Inf Model; 2013 Aug; 53(8):2093-102. PubMed ID: 23937544 [TBL] [Abstract][Full Text] [Related]
30. Druggability of the CK2 inhibitor CX-4945 as an anticancer drug and beyond. Kim J; Kim SH Arch Pharm Res; 2012 Aug; 35(8):1293-6. PubMed ID: 22941473 [TBL] [Abstract][Full Text] [Related]
31. Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth. Pizzi M; Piazza F; Agostinelli C; Fuligni F; Benvenuti P; Mandato E; Casellato A; Rugge M; Semenzato G; Pileri SA Oncotarget; 2015 Mar; 6(9):6544-52. PubMed ID: 25788269 [TBL] [Abstract][Full Text] [Related]
33. CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway. Prins RC; Burke RT; Tyner JW; Druker BJ; Loriaux MM; Spurgeon SE Leukemia; 2013 Oct; 27(10):2094-6. PubMed ID: 23900138 [No Abstract] [Full Text] [Related]
34. Addiction to protein kinase CK2: a common denominator of diverse cancer cells? Ruzzene M; Pinna LA Biochim Biophys Acta; 2010 Mar; 1804(3):499-504. PubMed ID: 19665589 [TBL] [Abstract][Full Text] [Related]
35. CK2 inhibition with silmitasertib promotes methuosis-like cell death associated to catastrophic massive vacuolization of colorectal cancer cells. Silva-Pavez E; Villar P; Trigo C; Caamaño E; Niechi I; Pérez P; Muñoz JP; Aguayo F; Burzio VA; Varas-Godoy M; Castro AF; Colombo MI; Tapia JC Cell Death Dis; 2019 Jan; 10(2):73. PubMed ID: 30683840 [TBL] [Abstract][Full Text] [Related]
36. MEK inhibitor PD-0325901 overcomes resistance to CK2 inhibitor CX-4945 and exhibits anti-tumor activity in head and neck cancer. Bian Y; Han J; Kannabiran V; Mohan S; Cheng H; Friedman J; Zhang L; VanWaes C; Chen Z Int J Biol Sci; 2015; 11(4):411-22. PubMed ID: 25798061 [TBL] [Abstract][Full Text] [Related]
37. 4,5,7-Trisubstituted indeno[1,2-b]indole inhibits CK2 activity in tumor cells equivalent to CX-4945 and shows strong anti-migratory effects. Birus R; El-Awaad E; Ballentin L; Alchab F; Aichele D; Ettouati L; Götz C; Le Borgne M; Jose J FEBS Open Bio; 2022 Feb; 12(2):394-411. PubMed ID: 34873879 [TBL] [Abstract][Full Text] [Related]
38. Chemically induced degradation of CK2 by proteolysis targeting chimeras based on a ubiquitin-proteasome pathway. Chen H; Chen F; Liu N; Wang X; Gou S Bioorg Chem; 2018 Dec; 81():536-544. PubMed ID: 30245235 [TBL] [Abstract][Full Text] [Related]
39. ER stress signaling in ARPE-19 cells after inhibition of protein kinase CK2 by CX-4945. Intemann J; Saidu NE; Schwind L; Montenarh M Cell Signal; 2014 Jul; 26(7):1567-75. PubMed ID: 24686080 [TBL] [Abstract][Full Text] [Related]
40. CX-4945 (Silmitasertib) Induces Cell Death by Impairing Lysosomal Utilization in Lee DS; Han MW; Kang Y; Kim C; Lee S; Kim KP; Yoo C Anticancer Res; 2024 May; 44(5):1939-1946. PubMed ID: 38677763 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]